NCT02269293View on ClinicalTrials.gov

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 13, 2014

Primary Completion Date

April 20, 2021

Study Completion Date

April 20, 2021

Conditions

Ovarian CancerEndometrial Cancer

Interventions

DRUG

Paclitaxel

DRUG

Carboplatin

DRUG

Selinexor

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

07748

Memoral Sloan Kettering Monmouth, Middletown

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02269293 - Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | Biotech Hunter | Biotech Hunter